Thursday, December 10, 2015 - 6:00 - 11:00 pm Welcome Reception

06:00 -
07:30 pm
Opening Ceremony at the Old Town Hall
Dr. Volker Rodekamp
(Director of the Leipzig Museum of City History)
07:30 -
11:00 pm
Welcome Reception at the Old Stock Exchange, Leipzig



Friday, December 11, 2015


08:30 -
10:00 am
Plenary Session 1
Chairs: J. Thiery, M. Tschöp
Gastric bypass without the surgery? Re-inventing obesity therapy
Matthias Tschöp (Germany)
Bile acid signaling as novel therapeutic target in non-alcoholic fatty liver disease
Michael Trauner (Austria)
Non-alcoholic steatohepatitis and cardiovascular disease: modulation by PPAR agonists
Bart Staels (France)
10:00 -
10:30 am
Coffee Break

10:30 am -
12:30 pm

WS1: Adipose Tissue and Lipid Biology

Chair: M. Blüher, M. Trauner

WS2: Lipoprotein metabolism and dyslipidemia

Chair: C. Lamina, G. Lambert

Size matters: an adipo(cyte)-centric view
Matthias Blüher (Germany)
News from the mysterious Lipoprotein(a)
Claudia Lamina (Austria)
Relevance and mechanism of lipoprotein uptake into brown adipose tissue
Jörg Heeren (Germany)
The PCSK9 Saga: from discovery to therapy
Gilles Lambert (Réunion)
A central role for Nfe2l1 in ER adaptation and mitochondrial health in brown fat  
Alexander Bartelt (USA)
Dyslipidemia in lipase-deficient mouse models
Dagmar Kratky (Austria)
FGF21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues 
Ludger Scheja (Germany)
Markedly altered metabolism of plasma LDL in the arterial wall precedes atherosclerosis regression
Lars-Bo Nielson (Denmark)
Increased hepatic bile acid production shapes the gut microbiome after cold induced brown adipose tissue activation
Anna Worthmann (Germany)
Impaired conjugated bile acid uptake in the liver reduces serum cholesterol and stimulates biliary cholesterol excretion
Reinout Roscam Abbing (Netherlands)
Dysregulation of Lysophospholipid and Sphingolipid Signaling in Diabesity and Vascular Disease
Gerd Schmitz (Germany)
PCSK9 Association with Lipoproteins: Biogenesis, Function, and Therapeutic Implications
Hagai Tavori (USA)
12:30 -
02:00 pm

Lunch Break

02:00 -
04:00 pm
Plenary Session 2
Chairs: D. Teupser, P. Elliott

Chemokines and microRNAs in atherosclerosis
Christian Weber (Germany)

Role of Non-coding RNAs in regulating lipid metabolism
Carlos Fernandez-Hernando (USA)
Metabolome-wide Association Studies in Cardio-metabolic Disease
Paul Elliott (UK)
Fighting cholesterol with cyclic oligosaccharides in atherosclerosis
Eike Latz (USA/ Germany)
04:00 -
04:30 pm
Coffee Break
04:30 -
05:50 pm
WS3: High-Density Lipoproteins
Chairs: A. von Eckardstein, S. Hofmann
WS4: Apolipoproteins and Metabolic Pathways
Chairs: U. Ceglarek, B. Fuhrmann
The role of the endothelium for metabolism and anti-atherogenicity of HDL
Arnold von Eckardstein (Switzerland)
Characterization of apolipoprotein distributions in human lipoprotein fractions and serum in the Leipzig Heart Study
Uta Ceglarek (Germany)

Low circulating HDL levels promote hypothalamic astrogliosis and metabolic disease in mice

Susanna Hofmann (Germany)

Atherosclerosis and Fibrinolysis- Two closely intertwined diseases
Bianca Fuhrmann (Israel)
Brown and beige adipocyte activity controls metabolic flux through the HDL compartment
Nicola Schaltenberg (Germany)
Targeted mass spectrometric analysis of the cellular response to genetic and pharmacological perturbations of the LXR and SREBP pathway
Peter Blattmann (Switzerland)
HDL protein composition as a modulator of lipoprotein functionality: lessons from clinical cases and animals studies
Kyriakos Kypreos (Greece)
ATGL acts on neutrophil lipid droplets to regulate substrate availability for lipid mediator synthesis
Stefanie Schlager (Austria)



Saturday, December 12, 2015


08:30 -
10:00 am
Poster Session & Breakfast
Chairs: D. Kratky, J.-R. Nofer, H. Tavori, W. Herrmann, K. E. Kypreos
10:00 -
10:30 am
Coffee Break
10:30 am -
12:00 pm
Plenary Session 3
Chairs: J. Heeren, B. Staels
Adipose Tissue-Derived Lipids: Impact on Systemic Inflammation and Insulin Sensitivity
Phil Scherer (USA)
Link between cardiovascular disease and dementia – genetics and lipid metabolism
Ruth Frikke-Schmidt (Denmark)
Redistribution of conventional & non-conventional fat depots in lifestyle RCT; MRI Journey to the human body
Iris Shai (Israel/ USA)
12:00 -
01:30 pm
Lunch Break
12:15 -
01:15 pm
Sanofi-Aventis Lunch-Symposium
Lecture title: „Modern Management of Dyslipidemia in High Cardiovascular Risk Patients”
Chair: J. Thiery
Speaker: J. Heeren, E. Steinhagen-Thiessen
Hypercholesterolaemia is a major risk factor in the development of atherosclerosis and coronary heart disease (CHD). Recently, PCSK9-inhibitors have been identified as a new efficacious and well tolerated treatment option for individuals  with inadequately controlled LDL-C despite of intensive standard of care lipid lowering therapy. Validation of promising preliminary data on CV event rate reduction is currently ongoing in large outcomes trials.
01:30 -
02:50 pm
WS 5: Mechanisms and Modulators of atherosclerosis
Chairs: E. Lutgens, R. Burkhardt
WS 6: Genetic and Genomic Studies
Chairs: M. Scholz, F. W. Asselbergs
Co-stimulation in atherosclerosis: novel players and new therapeutic targets
Esther Lutgens (Netherlands)
Genome-Wide SNP and  Gene-Expression Analyses Point Towards Novel Mechanisms of Metabolite Regulation
Markus Scholz (Germany)

New insights into anti-atherogenic effects exerted by sphingosine-1-phosphate (S1P)

Jerzy-Roch Nofer (Germany)
Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets
Folkert Asselberg (Netherlands)
Adam17 in atherogenesis
Daniel Teupser (Germany)
Non-coding RNAs in atherosclerosis
Lesca Miriam Holdt (Germany)
Tribbles homolog-1  -a gene with many faces in metabolism and atherosclerosis
Ralph Burkhardt (Germany)
Associations between lipoprotein subfractions and genome-wide DNA methylation in KORA F4
Lilliane Pfeiffer (Germany)